Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Eichhorst, Barbara  [Clear All Filters]
Journal Article
Cramer P, von Tresckow J, Fink A-M, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol. 2024.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(19):1739-1754.
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, et al. Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol. 2020.
Fürstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dörfel S, Aldaoud A, von Tresckow J, et al. Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am J Hematol. 2021.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink A-M, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2023.
von Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, et al. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group. Ann Hematol. 2023.